Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 70 articles: HTML format

Single Articles

May 2026
1. YANG DD, Abdelnaser A, Haas AJ, Wala J, et al
   Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.
   Clin Cancer Res. 2026 May 11. doi: 10.1158/1078-0432.CCR-25-4900.
   PubMed     Abstract available
   
   
   
2. ZAIDI S, Kuo PH, Paiva Prudente T, Lacuna KP, et al
   Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.
   Clin Cancer Res. 2026;32:1766-1776.
   PubMed     Abstract available
   
   
   April 2026
3. SHARMA S, Mundhara N, Tekoglu E, Amaral A, et al
   Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target.
   Clin Cancer Res. 2026 Apr 29. doi: 10.1158/1078-0432.CCR-26-0642.
   PubMed     Abstract available
   
   
   
4. MAKOVEC A, Gustafson AP, Gandhi N, Rampalli S, et al
   B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups.
   Clin Cancer Res. 2026 Apr 21. doi: 10.1158/1078-0432.CCR-26-0322.
   PubMed     Abstract available
   
   
   March 2026
5. ANTONARAKIS ES, Cao Q, Catharine V, Carneiro BA, et al
   Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study.
   Clin Cancer Res. 2026 Mar 25. doi: 10.1158/1078-0432.CCR-25-4823.
   PubMed     Abstract available
   
   
   
6. MCKAY RR, Nazari SS, Elliott A, Smith N, et al
   Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.
   Clin Cancer Res. 2026 Mar 12. doi: 10.1158/1078-0432.CCR-25-4293.
   PubMed     Abstract available
   
   
   
7. SLOVIN S, Gao X, Wei XX, Oh DY, et al
   Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).
   Clin Cancer Res. 2026 Mar 4. doi: 10.1158/1078-0432.CCR-25-3052.
   PubMed     Abstract available
   
   
   
8. YU EY, Narayan V, Esposito G, Szmulewitz R, et al
   131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study.
   Clin Cancer Res. 2026 Mar 4. doi: 10.1158/1078-0432.CCR-25-4948.
   PubMed     Abstract available
   
   
   February 2026
9. JANI CT, Tran E, Zhang N, Tsai J, et al
   Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer.
   Clin Cancer Res. 2026 Feb 26. doi: 10.1158/1078-0432.CCR-25-3071.
   PubMed     Abstract available
   
   
   
10. MCBRIDE SM, Spratt DE, Kollmeier M, Abida W, et al
    Apalutamide + Abiraterone acetate plus Prednisone (AAP) + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase 2 Study.
    Clin Cancer Res. 2026 Feb 19. doi: 10.1158/1078-0432.CCR-25-3746.
    PubMed     Abstract available
    
    
    
11. MUNZUR AD, Herberts C, Kwan EM, Emmett L, et al
    Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
    Clin Cancer Res. 2026 Feb 6. doi: 10.1158/1078-0432.CCR-25-4001.
    PubMed     Abstract available
    
    
    January 2026
12. VALENTIN LOPEZ JC, Yu C, Knutson TP, Kobilka A, et al
    Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trial.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-2779.
    PubMed     Abstract available
    
    
    
13. BIDKAR AP, Bidlingmaier S, Wadhwa A, Mayne E, et al
    Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates.
    Clin Cancer Res. 2026 Jan 22. doi: 10.1158/1078-0432.CCR-25-4110.
    PubMed     Abstract available
    
    
    December 2025
14. KU AT, Shankavaram U, Trostel SY, Zhang H, et al
    Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-beta Activity Driving Tumor Recurrence.
    Clin Cancer Res. 2025;31:5211-5224.
    PubMed     Abstract available
    
    
    
15. SAYEGH N, Graf RP, Swami U, Ozay ZI, et al
    Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Dec 4. doi: 10.1158/1078-0432.CCR-25-2750.
    PubMed     Abstract available
    
    
    
16. MEDINA S, Tokuyama N, Hammouda K, Pathak T, et al
    A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.
    Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-3327.
    PubMed     Abstract available
    
    
    
17. MORRIS MJ, Flynn J, Zhao B, Anand A, et al
    Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-2890.
    PubMed     Abstract available
    
    
    November 2025
18. MCHUGH D, Dallos M, Teo MY, McBride SM, et al
    Accelerating Drug Development in Hormone-Naive Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
    Clin Cancer Res. 2025 Nov 20. doi: 10.1158/1078-0432.CCR-25-2679.
    PubMed     Abstract available
    
    
    October 2025
19. NYQUIST MD, Nelson P
    Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle.
    Clin Cancer Res. 2025 Oct 29. doi: 10.1158/1078-0432.CCR-25-3045.
    PubMed     Abstract available
    
    
    
20. BOUZAKI A, Vasquez Osorio E, Kerns S, van Herk M, et al
    Integration of dose surface maps and genetic data identifies the lower posterior rectum as a key region for toxicity after prostate cancer radiotherapy.
    Clin Cancer Res. 2025 Oct 13. doi: 10.1158/1078-0432.CCR-25-2102.
    PubMed     Abstract available
    
    
    
21. BRIGHI N, Wetterskog D, Vainauskas O, Orlando F, et al
    Liquid biopsy identifies taxane resistance and clonal selection in castration-resistant prostate cancer.
    Clin Cancer Res. 2025 Oct 13. doi: 10.1158/1078-0432.CCR-25-2121.
    PubMed     Abstract available
    
    
    September 2025
22. BLINKA S, Yu EY
    Drug targets in prostate cancer: an appetite for KLK2-mediated destruction.
    Clin Cancer Res. 2025 Sep 9. doi: 10.1158/1078-0432.CCR-25-2546.
    PubMed     Abstract available
    
    
    August 2025
23. OWIREDU J, Ersoy-Fazlioglu B, Poluben L, Calagua C, et al
    Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancer.
    Clin Cancer Res. 2025 Aug 12. doi: 10.1158/1078-0432.CCR-22-3683.
    PubMed     Abstract available
    
    
    
24. NAYAK S, Norris JD, Ammirante M, Rychak E, et al
    Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0471.
    PubMed     Abstract available
    
    
    
25. JIAO J, Ma S, Wu P, Song X, et al
    Transrectal Ultrasound-Guided Prostate Biopsy With and Without PSMA PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0320.
    PubMed     Abstract available
    
    
    July 2025
26. GRAHAM LS, Yu EY
    Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer.
    Clin Cancer Res. 2025 Jul 31. doi: 10.1158/1078-0432.CCR-25-2359.
    PubMed     Abstract available
    
    
    
27. AGGARWAL R, Rottey S, Bernard-Tessier A, Mellado B, et al
    Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
    Clin Cancer Res. 2025 Jul 21. doi: 10.1158/1078-0432.CCR-25-1211.
    PubMed     Abstract available
    
    
    
28. MAGUIRE WF, Chi DC, Agrawal S, Joeng HK, et al
    FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Jul 17. doi: 10.1158/1078-0432.CCR-25-0883.
    PubMed     Abstract available
    
    
    
29. PATEL RB, Adler SS, Escorcia FE
    Size Matters: Superior Efficacy of alpha Particle Radioimmunotherapy in Micrometastases versus Macrometastases.
    Clin Cancer Res. 2025;31:2847-2849.
    PubMed     Abstract available
    
    
    
30. SHEN F, Smith R, McDevitt T, Menard K, et al
    Human kallikrein 2: A novel lineage-specific surface target in prostate cancer.
    Clin Cancer Res. 2025 Jul 8. doi: 10.1158/1078-0432.CCR-25-0950.
    PubMed     Abstract available
    
    
    June 2025
31. HAGE CHEHADE C, Graf RP, Ozay ZI, Gebrael G, et al
    Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer.
    Clin Cancer Res. 2025 Jun 16. doi: 10.1158/1078-0432.CCR-25-1178.
    PubMed     Abstract available
    
    
    May 2025
32. DEV H, Linch M, Narahari K, Milne-Clark T, et al
    Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib +/- Degarelix in Primary Prostate Cancer.
    Clin Cancer Res. 2025 May 13:OF1-OF11. doi: 10.1158/1078-0432.CCR-24-1304.
    PubMed     Abstract available
    
    
    
33. ARAFA AT, Yadav S, Marshall CH, Mauer E, et al
    Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.
    Clin Cancer Res. 2025;31:1730-1745.
    PubMed     Abstract available
    
    
    April 2025
34. WERNECK GOMES H, Lister NL, Keerthikumar S, Niranjan B, et al
    p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancer.
    Clin Cancer Res. 2025 Apr 25. doi: 10.1158/1078-0432.CCR-24-3848.
    PubMed     Abstract available
    
    
    
35. SHAH K, Secrest MH, Zhou W, Wang S, et al
    Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
    Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1812.
    PubMed     Abstract available
    
    
    
36. KISHAN AU, McGreevy K, Valle L, Steinberg M, et al
    Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3951.
    PubMed     Abstract available
    
    
    March 2025
37. MCNEVIN CS, Keogh A, Mohammed Nur M, McGovern B, et al
    Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort.
    Clin Cancer Res. 2025 Mar 19:OF1-OF8. doi: 10.1158/1078-0432.CCR-24-1210.
    PubMed     Abstract available
    
    
    
38. ZHANG L, Teng PC, Cavassani KA, Wang J, et al
    Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer.
    Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-3660.
    PubMed     Abstract available
    
    
    
39. HWANG J, Likasitwatanakul P, Deshmukh SK, Wu S, et al
    Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.
    Clin Cancer Res. 2025;31:936-948.
    PubMed     Abstract available
    
    
    February 2025
40. BJARTELL A, Krzyzanowska A, Liu VYT, Tierney M, et al
    Validation of a digital pathology-based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy.
    Clin Cancer Res. 2025 Feb 21. doi: 10.1158/1078-0432.CCR-24-3656.
    PubMed     Abstract available
    
    
    
41. GALSKY MD, Autio KA, Cabanski CR, Wentzel K, et al
    Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693.
    PubMed     Abstract available
    
    
    
42. BIDKAR AP, Peter R, Wadhwa A, Bobba KN, et al
    Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
    Clin Cancer Res. 2025 Feb 13. doi: 10.1158/1078-0432.CCR-24-2850.
    PubMed     Abstract available
    
    
    January 2025
43. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    PubMed     Abstract available
    
    
    
44. ANDREWS J, Kim Y, Horjeti E, Arafa A, et al
    PSMA+ Extracellular Vesicles are a Biomarker for SABR in Oligorecurrent Prostate Cancer Analysis from the STOMP-like and ORIOLE trial cohorts.
    Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-3027.
    PubMed     Abstract available
    
    
    
45. WELTI J, Bogdan D, Figueiredo I, Coleman I, et al
    NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2386.
    PubMed     Abstract available
    
    
    November 2024
46. HAFFNER MC, Morris MJ, Ding CC, Sayar E, et al
    Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2061.
    PubMed     Abstract available
    
    
    
47. WINQUIST E, Hotte SJ, Chi K, Sridhar S, et al
    Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1612.
    PubMed     Abstract available
    
    
    
48. NAWFAL R, El Hajj Chehade R, Berchuck JE
    Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.
    Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-2849.
    PubMed     Abstract available
    
    
    October 2024
49. STOPSACK KH, Vijai J, Conry M, Berchuck JE, et al
    Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.
    Clin Cancer Res. 2024 Oct 25. doi: 10.1158/1078-0432.CCR-24-2483.
    PubMed     Abstract available
    
    
    September 2024
50. ISAACSSON VELHO P, Bastos DA, Saint'ana PT, Rigatti B, et al
    Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects.
    Clin Cancer Res. 2024 Sep 27. doi: 10.1158/1078-0432.CCR-24-1595.
    PubMed     Abstract available
    
    
    
51. CHOU J, Robinson TM, Egusa EA, Lodha R, et al
    Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-23-3785.
    PubMed     Abstract available
    
    
    
52. JENSEN JL, Bobek O, Chan ICC, Miller BC, et al
    Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
    Clin Cancer Res. 2024 Sep 17:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0803.
    PubMed     Abstract available
    
    
    
53. DALLOS MC, Obradovic AZ, McCann P, Chowdhury N, et al
    Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-0060.
    PubMed     Abstract available
    
    
    August 2024
54. CHAUHAN PS, Alahi I, Sinha S, Ledet EM, et al
    Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-1658.
    PubMed     Abstract available
    
    
    
55. HUSSAIN M, Kocherginsky M, Agarwal N, Adra N, et al
    Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
    Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-1402.
    PubMed     Abstract available
    
    
    
56. NGUYEN CB, Reimers MA, Perera C, Abida W, et al
    Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
    Clin Cancer Res. 2024;30:3200-3210.
    PubMed     Abstract available
    
    
    July 2024
57. SWEENEY CJ, Petry R, Xu C, Childress M, et al
    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-1096.
    PubMed     Abstract available
    
    
    
58. LENIS AT, Ravichandran V, Brown S, Alam SM, et al
    Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
    Clin Cancer Res. 2024 Jul 1. doi: 10.1158/1078-0432.CCR-23-3403.
    PubMed     Abstract available
    
    
    April 2024
59. APARICIO AM, Tidwell RSS, Yadav SS, Chen JS, et al
    A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740.
    PubMed     Abstract available
    
    
    
60. ARCHER S, Brailey PM, Song M, Bartlett PD, et al
    CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.
    Clin Cancer Res. 2024;30:1595-1606.
    PubMed     Abstract available
    
    
    
61. SCHATZ CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al
    Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
    Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746.
    PubMed     Abstract available
    
    
    
62. CHO H, Byun SS, Son NH, Chung JI, et al
    Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
    Clin Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-3083.
    PubMed     Abstract available
    
    
    March 2024
63. DESAI KB, Serritella AV, Stadler WM, O'Donnell PH, et al
    A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636.
    PubMed     Abstract available
    
    
    
64. AGARWAL N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, et al
    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
    Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436.
    PubMed     Abstract available
    
    
    
65. ANSELMINO N, Labanca E, Shepherd PDA, Dong J, et al
    Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.
    Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-23-2438.
    PubMed     Abstract available
    
    
    February 2024
66. VELLKY JE, Kirkpatrick BJ, Gutgesell LC, Morales M, et al
    ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.
    Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161.
    PubMed     Abstract available
    
    
    
67. DORFF T, Horvath LG, Autio K, Bernard-Tessier A, et al
    A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
    PubMed     Abstract available
    
    
    January 2024
68. HALABI S, Guo S, Park JJ, Nanus DM, et al
    The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-3017.
    PubMed     Abstract available
    
    
    
69. ABIDA W, Hahn AW, Shore N, Agarwal N, et al
    Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide.
    Clin Cancer Res. 2024 Jan 16. doi: 10.1158/1078-0432.CCR-23-3508.
    PubMed     Abstract available
    
    
    September 2023
70. CHAUDAGAR K, Hieromnimon HM, Kelley A, Labadie B, et al
    Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
    Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum